

Substipharm and Athena Pharmaceutiques Acquire Controlling Interest in Vectans Pharma to Drive Global Growth and Innovation

PRESS RELEASE

Paris, July 2, 2025 –Substipharm SAS and Athena Pharmaceutiques, today announced the acquisition of a majority stake in Vectans Pharma SAS, a pharmaceutical company recognized for its proprietary Lauriad® muco-adhesive drug delivery technology.

Vectans Pharma has successfully developed and globally licensed two flagship products, Loramyc® (miconazole Lauriad®) and Sitavig® (acyclovir Lauriad®) and is actively advancing its pipeline with new therapeutic applications in infectious diseases, supportive oncology, and mucosal conditions.

This alliance leverages the strengths of Substipharm and Athena to fast-track Vectans Pharma's innovation pipeline and broaden its global footprint. It creates a robust platform to grow the Lauriad® franchise, enter new markets, and enhance value through streamlined operations.

"The investment by Athena Pharmaceutiques and Substipharm marks a pivotal milestone for Vectans Pharma. It positions us to accelerate our growth trajectory while preserving the scientific excellence and entrepreneurial agility that define our company's DNA." Jérôme Theron, CEO of Vectans Pharma

"This acquisition is fully aligned with our strategic focus on high-value, innovation-led platforms with strong global potential," said Léopold Berthier, Substipharm's CEO. "We are excited to support Vectans Pharma in scaling its unique delivery technology and advancing its scientific and commercial objectives worldwide."

About Substipharm SAS

Substipharm is an independent French biopharmaceutical company active in the development, registration, and commercialization of generic or specialty drugs and vaccines. With a diversified portfolio and commercial presence in over 90 countries, Substipharm supports global access to essential treatments.

<https://www.substipharm.com>

About Athena Pharmaceutiques

Athena Pharmaceutiques is a French pharmaceutical group with three industrial and R&D sites across France and India, supported by a team of over 500 professionals. The company develops, manufactures, and licenses oral solid dosage forms, with commercial reach in more than 50 countries. In France, Athena markets partner's products through its subsidiary, Médipha Santé.

<https://www.athenapharmaceutiques.com>

contact@ddsathena.com

About Vectans Pharma

Vectans Pharma is a privately held French biopharmaceutical company specializing in the development of muco-adhesive treatments based on its proprietary Lauriad® technology. Its mission is to enhance treatment adherence, efficacy, and tolerability for conditions affecting the oral and vaginal mucosa. Vectans currently markets two innovative, best-in-disease drugs for the treatment of cold sores and oropharyngeal candidiasis, which are distributed in 78 countries through a network of 17 global partners. The company also has a pipeline of over 10 innovative drug candidates formulated using its Lauriad® muco-adhesive technology.

<https://www.vectanspharma.com>

contact@vectans.com